Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 4...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Angiogenesis
Auteurs principaux: Faughnan, Marie E., Gossage, James R., Chakinala, Murali M., Oh, S. Paul, Kasthuri, Raj, Hughes, Christopher C. W., McWilliams, Justin P., Parambil, Joseph G., Vozoris, Nicholas, Donaldson, Jill, Paul, Gitanjali, Berry, Pamela, Sprecher, Dennis L.
Format: Artigo
Langue:Inglês
Publié: Springer Netherlands 2018
Sujets:
Original Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510884/
https://ncbi.nlm.nih.gov/pubmed/30191360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-018-9646-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires